How Kalshi clinical trial markets resolve—and what to check before trading
Learn who decides Kalshi clinical trial outcomes, which documents count, and how deadlines, spreads and fees affect a beginner’s trade.
A Kalshi clinical trial market does not settle on whether a drug sounds promising. It settles on the specific question, deadline, evidence sources and criteria in its contract terms. As of October 1, 2026, AppliedXL’s pilot FAQ describes this process: AppliedXL supplies resolution analysis and supporting public evidence; Kalshi has sole authority to determine and finalize the outcome. AppliedXL’s pilot FAQ
The practical question before buying is: What exact evidence would make this contract resolve Yes? Your view of the science is useful only after you understand that condition.
Three questions that must stay separate
The Kalshi–AppliedXL pilot announced in July 2026 covers selected late-stage trial outcomes and FDA regulatory decisions. These are not interchangeable events:
| Contract question | What to identify in the rules | What not to substitute |
|---|---|---|
| Does a trial meet its primary endpoint? | The exact trial, endpoint, analysis criteria and designated public record | A positive secondary endpoint or an upbeat headline |
| Does the FDA approve a drug by a deadline? | The drug, any specified indication, deadline and FDA source | Trial success or an advisory committee recommendation |
| What is the advisory committee’s vote? | The exact voting question, required result and official vote record | A later FDA decision |
AppliedXL notes that statistical significance does not necessarily establish clinical significance, and a successful trial does not necessarily lead to approval. A binary contract answers its defined question—not every question about the treatment’s usefulness or safety. Its resolution explanation makes these distinctions explicit.
Read the full source rule, not just the title
The launch announcement emphasizes ClinicalTrials.gov records, FDA approval letters and advisory committee voting records. AppliedXL’s more detailed FAQ says a contract can also identify other institutional records or an official company disclosure. Do not assume all sponsor announcements are excluded—or that every sponsor announcement counts. The individual contract’s permitted sources and source hierarchy govern. Source rules and review process
Before placing an order, write down:
- Identity: Which drug, trial identifier, patient population and endpoint does the contract name?
- Yes condition: What result, statistical threshold or regulatory action satisfies it? If there are multiple primary endpoints, how are they treated?
- Evidence: Which document counts, and which source takes priority if records disagree?
- Timing: What must happen by the deadline—an event, a disclosure or publication in a particular source?
- Exceptions: How do the terms handle missing results, revised records, delays or ambiguity?
Do not invent a default such as “no published results means No.” AppliedXL says exceptional circumstances are handled under the applicable contract terms and Kalshi’s rules. Its process includes human review of the evidence before submitting an analysis to Kalshi; it is not solely an automated interpretation. AppliedXL’s resolution process
Also separate trading close, the event deadline and determination time. Kalshi explains that displayed close time need not equal determination time; settlement may wait for official data or a later rules-specified determination window. A press release appearing does not necessarily mean your payout is immediately available. Kalshi’s settlement FAQ
One hypothetical contract: wording first, arithmetic second
This is an illustration, not a live market or an actual trial rule.
Assume a contract requires the designated public results record to show that a specified primary endpoint meets p < 0.05, with all other timing and analysis conditions satisfied. Suppose that record reports p = 0.08 for the primary endpoint but p = 0.01 for a secondary endpoint. Under those hypothetical terms, the answer is No: the secondary result does not satisfy the primary-endpoint condition.
To see what that means financially, assume that before those results were known:
- The Yes bid was 58¢ and the Yes ask was 62¢, with enough contracts available at those prices.
- You bought 10 Yes contracts at 62¢ and held to ordinary binary settlement.
- Total fees for that buy-and-hold example were an assumed $0.20; taxes are excluded.
- A winning contract pays $1; a losing contract pays $0. This is the standard binary payout framework described by the CFTC.
Your cost is 10 × $0.62 + $0.20 = $6.40. A Yes settlement would return $10, leaving $3.60 after the assumed fees. The hypothetical No settlement returns $0, losing $6.40.
Your fee-adjusted break-even probability at purchase was $6.40 ÷ $10 = 64%, not 62%. That probability must refer to the exact contract condition—not “the drug eventually succeeds.” The four-cent spread matters too: immediately selling at the unchanged 58¢ bid would lose 10 × $0.04 = $0.40 before fees.
The $0.20 fee is only an assumption. Check the actual order costs and Kalshi’s current fee schedule.
If you cannot identify the document and condition that would settle the market, leave the price analysis until later. Use the broader pre-trade reading checklist once that resolution question is clear. This is market-literacy education, not trading or medical advice.